Policy & News
The company organised the election for the fifth session of the People's Congress of Xinbei District
2023-01-09
According to the arrangement of the general election work of Xinbei District People's Congress Election Committee, the voter group of Jiangsu Kangrun Biotechnology Co., Ltd. in the second constituency of Xinqiao Street, Xinbei District, voted for the election on 6 December 2021, and 127 employees of the company took part in the voting.
View More
World's first new plant-based crown vaccine approved in Canada
2023-01-09
Canada has become the first country in the world to authorise the use of a plant-based New Crown vaccine, ABC reports. On 24 February local time, Canadian regulators said they were allowing two doses of Medicago's New Crown vaccine to be administered to adults between the ages of 18 and 64, but said there was still too little data related to people aged 65 and older.
View More
Five Chinese drugmakers licensed to make generic versions of Pfizer's new Crown oral drug
2023-01-09
On 18 March Beijing time, the official website of Geneva Medicines PatentPool (MPP) announced that it had signed agreements with 35 companies, which were allowed to produce generic versions of nirmatrelvir, one of the components of Pfizer's new crown jewel, Paxlovid, as APIs or preparations.
View More
2023-01-09
Recently, two new inactivated coronavirus vaccines (Omicron variant, hereinafter referred to as "O-strain") developed by Sinopharm's China Biologicals Beijing Bioproducts Research Institute and Wuhan Bioproducts Research Institute have been approved by the Research Ethics Committee of the University of Hong Kong and Hong Kong Island West Hospital of the Hospital Authority, as well as by the Clinical Trial Approval from the Pharmacy and Poisons Board of Hong Kong, and have been formally authorised to carry out a sequential immunisation clinical study of the new coronavirus vaccines in Hong Kong.
View More
Sinopharm, Kexing Omicron variant of new crown vaccine approved for clinical use in China
2023-01-09
On 26 April, Sinopharm China Biotechnology Company Limited and Kexing Holdings Biotechnology Company Limited announced that their Omicron variant strain of inactivated neocoronavirus vaccine had been granted clinical approval by China's State Drug Administration respectively.
View More
Hand in hand to build the dream of Kangrun
2023-01-09
On the morning of 22nd July, 2022, the new staff development training with the theme of "Youthful Excitement, Creating Brilliance, Pursuing Excellence and Embodying Values" kicked off in Jintan, Changzhou. The new staff development was carried out in two batches, with a total of more than 130 employees participating in the training. The training aims to enhance communication and understanding between employees, strengthen team cohesion and centripetal force, and create a unity and mutual help, positive and upward corporate culture atmosphere.
View More
